StemCell Institute
7096.TPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 |
|---|---|---|
| Revenue | ¥2.8bn | — |
| Operating income | ¥203m | — |
| Ordinary income | ¥217m | — |
| Net income (owners) | ¥156m | — |
| Total assets | ¥8.1bn | — |
| Net assets / equity | ¥3.1bn | ¥2.6bn |
| Operating cash flow | ¥74m | — |
| EPS (basic) | ¥15.44 | — |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 4
| Period | Form | Figures |
|---|---|---|
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 44 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 68 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 42 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 104 figures · EDINET |
4 more reports are still being processed.